Ofloxacin + OrnidazoleThird Party Manufacturing in India

Ofloxacin + Ornidazole is a broad-spectrum anti-infective fixed-dose combination that works through two complementary mechanisms to treat mixed aerobic and anaerobic infections.

Ofloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA gyrase and topoisomerase IV. These enzymes are essential for bacterial DNA replication, transcription, repair, and recombination. By binding to these targets, Ofloxacin prevents the supercoiling and unwinding of bacterial DNA, effectively halting cell division and leading to bacterial cell death. It is particularly active against aerobic Gram-negative and Gram-positive bacteria.

Ornidazole, a nitroimidazole derivative, enters microbial cells by passive diffusion. Once inside, its nitro group is reduced by bacterial nitroreductases to form reactive intermediates and free radicals. These cytotoxic compounds damage microbial DNA, causing strand breakage and inhibiting nucleic acid synthesis. Ornidazole is highly effective against anaerobic bacteria and protozoa.

Together, this combination provides comprehensive coverage against mixed infections involving both aerobic and anaerobic pathogens. It is especially useful in surgical prophylaxis, intra-abdominal infections, pelvic inflammatory disease, and post-operative septic conditions where polymicrobial involvement is common. The synergistic action of both molecules reduces the likelihood of resistance development compared to monotherapy.

Therapeutic Uses

Ofloxacin + Ornidazole infusion is prescribed for the treatment of mixed aerobic and anaerobic infections:

• Intra-abdominal Infections: Peritonitis, appendicitis, cholangitis, and other surgical infections involving the gastrointestinal tract where mixed bacterial flora are present.
• Pelvic Inflammatory Disease (PID): Effective against sexually transmitted pathogens including Chlamydia trachomatis, Neisseria gonorrhoeae, and mixed anaerobic bacteria.
• Post-Surgical Infections: Prophylactic and therapeutic use in post-operative wound infections, especially following abdominal, gynecological, and colorectal surgeries.
• Genitourinary Tract Infections: Complicated urinary tract infections, prostatitis, and pyelonephritis with mixed aerobic-anaerobic involvement.
• Oral and Dental Infections: Severe odontogenic infections involving both aerobic and anaerobic oral flora.

Why Manufacturers Choose Ofloxacin + Ornidazole

Ofloxacin + Ornidazole is one of the most prescribed fixed-dose combination infusions in Indian hospitals due to its broad coverage and proven efficacy in mixed infections. The combination is included in numerous hospital formularies and antibiotic stewardship protocols for surgical prophylaxis. Its consistent demand from private hospitals, government institutions, and nursing homes makes it a high-volume product for third-party manufacturers. The 100ml IV infusion format is a standardized hospital item with year-round procurement cycles.

This makes Ofloxacin + Ornidazole infusion one of the most sought-after combination products for third party manufacturing in India, with reliable demand from institutional buyers, PCD franchise networks, and export-oriented pharmaceutical companies.